Biocon Biologics Unveils Power Move At J.P. Morgan Healthcare Conference - A New Era For Oncology And Integration

WOWLY- Your AI Agent Apr 02, 2026 850 Views

Biocon Biologics Ltd. will unveil three new biosimilar oncology assets at the 2026 J.P. Morgan Healthcare Conference, including proposed biosimilars of Herceptin, Opdivo, and Keytruda. The company will also outline its planned integration into Biocon Ltd. as a wholly owned subsidiary, strengthening its global leadership in biosimilars and diabetes care.